Akari Therapeutics, Plc (AKTX) Research
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
Market snapshot
- Symbol
- AKTX
- Price
- $10.94
- Day change
- -8.83%
- Market cap
- $12.5M
- P/E ratio
- -0.01x
- 52-week range
- 3.015-49.6
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $1,200
Recent news
- Why Akari Therapeutics Stock Is Falling On Tuesday?
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
- Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated pancreatic cancer models.
Peer companies
Recent insider activity
- Neal James R — P-Purchase (3093 shares) on 2025-12-16
- Neal James R — P-Purchase (3093 shares) on 2025-12-16
- Neal James R — P-Purchase (2473 shares) on 2025-12-16
- Neal James R — P-Purchase (2473 shares) on 2025-12-16
- Prudo-Chlebosz Raymond — P-Purchase (618658 shares) on 2025-12-16
Open Akari Therapeutics, Plc (AKTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.